3381-73-5

Basic information

• Product Name: ALPHA-BROMO-4-CHLOROPHENYLACETIC ACID
• Synonyms: 2-BroMo-2-(4-chlorophenyl)acetic acid;alpha-Bromo-p-chlorobenzeneacetic acid;^a-BroMo-4-chlorophenylacetic acid, 97%;α-bromo-4-chlorophenylacetic acid;ALPHA-BROMO-(4-CHLOROOPHENYL) ACETIC ACID METHYL ESTER
• CAS NO: 3381-73-5
• Molecular Formula: C₈H₆BrClO₂
• Molecular Weight: 249.49
• Product Categories: Carbonyl Compounds;Carboxylic Acids;C8
• Mol File: 3381-73-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 95-99 °C
• Boiling Point: 326.099 °C at 760 mmHg
• Flash Point: 151.02 °C
• Appearance: /
• Density: 1.747
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.618
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.27±0.10(Predicted)
• CAS DataBase Reference: ALPHA-BROMO-4-CHLOROPHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: ALPHA-BROMO-4-CHLOROPHENYLACETIC ACID(3381-73-5)
• EPA Substance Registry System: ALPHA-BROMO-4-CHLOROPHENYLACETIC ACID(3381-73-5)

Safety Data

• Hazard Codes: C
• Statements: 22-34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3261 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 3381-73-5(Hazardous Substances Data)

Usage

Uses

α-Bromo-?4-?chlorophenylacetic acid is a useful reactant or reagent in organic synthesis.

InChI:InChI=1/C8H6BrClO2/c9-7(8(11)12)5-1-3-6(10)4-2-5/h1-4,7H,(H,11,12)

Upstream product

• 1878-66-6 4-chlorophenylacetic Acid 
• 33512-03-7 3-(4-chlorophenyl)oxirane-2,2-dicarbonitrile 
• 6212-33-5 2-(4-Chlorophenyl)glycine 

Downstream Products

• 85592-32-1 α-(5-chlorobenzothiazol-2-ylthio)-α-(p-chlorophenyl)acetic acid 
• 655223-09-9 2-(2-propynyloxy)-2-(4-chlorophenyl)-acetic acid 
• 930779-79-6 (2S)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl 2-bromo-2-(4-chlorophenyl)acetate 
• 2387-23-7 1,3-Dicyclohexylurea 
• 1590450-42-2 N-benzoyl-O-[α-bromo-α-(p-chlorophenyl)acetyl]-L-threonine isopropyl ester 
• 1590450-46-6 N-benzoyl-O-[α-bromo-α-(p-chlorophenyl)acetyl]-L-threonine isopropyl ester 
• 1590450-63-7 (S)-2-(p-chlorophenyl)-2H-1,4-benzoxazin-3(4H)-one 
• 90705-87-6 C₁₁H₈BrClO₂ 
• 85592-38-7 α-[(5-chlorothiazolo[5,4-b]pyridin-2-yl)thio]-α-(p-chlorophenyl)acetic acid 
• 184879-14-9 methyl 2-(4-chlorophenyl)-2-(4-isopropylphenoxy)acetate 
• 24091-92-7 methyl 2-bromo-2-(4-chlorophenyl)acetate 
• 92873-46-6 2-benzylamino-5-(4-chloro-phenyl)-thiazol-4-one 
• 76881-06-6 2-anilino-5-(4-chloro-phenyl)-thiazol-4-one 
• 92426-95-4 2-(2-chloro-anilino)-5-(4-chloro-phenyl)-thiazol-4-one 

Relevant articles and documents

Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer

The bromodomain and extra-terminal proteins (BET) have emerged as promising therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We report the design, synthesis and evaluation of a new series of benzoxazinone-containing 3,5-dimethylisoxazole derivatives as selective BET inhibitors. One of the new compounds, (R)-12 (Y02234), binds to BRD4(1) with a Kd value of 110 nM and blocks bromodomain and acetyl lysine interactions with an IC50 value of 100 nM. It also exhibits selectivity for BET over non-BET bromodomain proteins and demonstrates reasonable anti-proliferation and colony formation inhibition effect in prostate cancer cell lines such as 22Rv1 and C4-2B. The BRD4 inhibitor (R)-12 also significantly suppresses the expression of ERG, Myc and AR target gene PSA at the mRNA level in prostate cancer cells. Treatment with (R)-12 significantly suppresses the tumor growth of prostate cancer (TGI = 70%) in a 22Rv1-derived xenograft model. These data suggest that compound (R)-12 is a promising lead compound for the development of a new class of therapeutics for the treatment of CRPC.

THE METHOD OF MAKING OPTICALLY ACTIVE 2-HALO-2-(N-SUBSTITUTED PHENYL)ACETIC ACID ESTERS AND 2-HALO-2-(N-SUBSTITUTED PHENYL)ACETIC ACIDS BY ENZYMATIC METHOD

The present invention relates to the process for the preparation of optically active 2-halo-2-(n-substituted phenyl)acetic acid esters and optically active 2-halo-2-(n-substituted phenyl)acetic acids, which are used intensively as important chiral intermediates, represented by general formula 2 and 3 respectively from racemic 2-halo-2-(n-substituted phenyl)acetic acid ester represented by general formula 1. In more detail, this invention relates to the process for preparing optically active 2-halo-2-(n-substituted phenyl)acetic acid esters and optically active 2-halo-2-(n-substituted phenyl)acetic acids by stereospecific hydrolysis of racemic 2-halo-2-(n-substituted phenyl)acetic acid esters using hydrolases or hydrolase-producing microorganisms in the aqueous phase or organic phase including aqueous solvent. This method is useful in the practical process because the production and separation of compounds with high optical purity is easier.

Process for the stereoselective preparation of (-)-halofenate and derivatives thereof

The present invention provides a compounds the formula (IV): and methods for producing an α-(phenoxy)phenylacetic acid compound of the formula: wherein R1 is a member selected from the group consisting of: each R2 is a member indepen